Mayo Clinic Researchers Use AI, Biomarkers to Personalize Rheumatoid Arthritis Treatment

Treatment options for rheumatoid arthritis have often relied on trial and error. Now Mayo Clinic researchers are exploring the use of artificial intelligence (AI) and pharmacogenomics to predict how patients will respond to treatments, and to personalize care. Findings were published in Arthritis Care & Research.

The study focused on predicting the response to methotrexate, one of the most common rheumatoid arthritis medications. Applying patient data that included genomic, clinical and demographic information, researchers used AI to determine an initial response to methotrexate in patients with early-stage rheumatoid arthritis. Data used in the study came from a collaboration between Mayo Clinic and the Pharmacogenetics of Methotrexate in Rheumatoid Arthritis (PAMERA) consortium, that led to early genome-wide association studies.

This work evolved from the union of AI and pharmacogenomics co-led by Liewei Wang; M.D., Ph.D., Arjun Athreya, Ph.D. and Richard Weinshilboum, M.D. "This approach began by developing tools to predict drug treatment outcomes in major depressive disorder, but we are delighted to see that it can potentially be applied widely, in this case to the drug therapy of rheumatoid arthritis," says pharmacogenomics leaders Drs. Wang and Weinshilboum.

"In my everyday practice, patients frequently ask, 'What medication will be most effective for me' or 'What is the chance this medication will help?' This is a study that seeks to address these questions," says Elena Myasoedova, M.D., Ph.D., a Mayo Clinic rheumatologist and lead author. By predicting a response to methotrexate, researchers identified which patients are most likely to benefit from this medication in the first three months of treatment.

More research is needed to understand how these findings can be used in practice. The study, which is part of a series looking at the roles of AI and pharmacogenomics in treating rheumatoid arthritis, was performed in collaboration with Mayo Clinic's Center for Individualized Medicine.

"Predicting a response to rheumatoid arthritis medication can be challenging, but this approach is very promising and is an exciting development in treating the disease," Dr. Myasoedova says.

Myasoedova E, Athreya AP, Crowson CS, Davis JM 3rd, Warrington KJ, Walchak RC, Carlson E, Kalari KR, Bongartz T, Tak PP, van Vollenhoven RF, Padyukov L, Emery P, Morgan A, Wang L, Weinshilboum RM, Matteson EL; PAMERA consortium.
Towards Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: a Pharmacogenomics-driven Machine Learning Approach.
Arthritis Care Res (Hoboken). 2021 Dec 13. doi: 10.1002/acr.24834

Most Popular Now

Health Fabric and Sandwell Council Secur…

Digital health company Health Fabric is preparing to work with Sandwell Council after learning that it has secured support from The Healthy Ageing Challenge. The company will work with public health...

Philips Highlights AI-Powered Precision …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, showcases its award-winning AI-powered systems and solutions debuting at the European Congress of Radiology (ECR, July 13-17, Vienna...

Could a Computer Diagnose Alzheimer's Di…

It takes a lot of time - and money - to diagnose Alzheimer's disease. After running lengthy in-person neuropsychological exams, clinicians have to transcribe, review, and analyze every response in...

Siemens Healthineers Accelerates and Imp…

Siemens Healthineers presents functionalities powered by Artificial Intelligence (AI) that accelerate and improve Magnetic Resonance Imaging (MRI). The quality of MR imaging is defined by the trade-off between scan time...

Building the Right Foundations to Delive…

Opinion Article by Gary Birks, Gary Birks, General Manager, UK and Ireland, Orion Health. The latest strategy for health and care IT looks to build on what has been achieved over...

Using Technology to Support Primary Care

Opinion Article by Paul Bensley, Managing Director of Primary Care Cloud Telephony Specialist X-on. It is good to see the publication of this strategy [A plan for digital health and social...

A Machine Learning Model to Predict Immu…

Immunotherapy is a new cancer treatment that activates the body's immune system to fight against cancer cells without using chemotherapy or radiotherapy. It has fewer side effects than conventional anticancer...

Virtual Reality App Trial Shown to Reduc…

Results from a University of Otago, Christchurch trial suggest fresh hope for the estimated one-in-twelve people worldwide suffering from a fear of flying, needles, heights, spiders and dogs. The trial, led...

Two Leading CIOs Join the Highland Marke…

Two of the NHS' most dynamic chief information officers have joined Highland Marketing’s advisory board of NHS IT professionals and health tech industry experts. Ian Hogan, a CIO at the Northern...

Teaching AI to Ask Clinical Questions

Physicians often query a patient's electronic health record for information that helps them make treatment decisions, but the cumbersome nature of these records hampers the process. Research has shown that...

AI Analyses Neuron Changes to Detect whe…

A research group from Nagoya University in Japan has developed an artificial intelligence (AI) for analyzing cell images that uses machine learning to predict the therapeutic effect of drugs. Called...

MIT Engineers Develop Stickers that can …

Ultrasound imaging is a safe and noninvasive window into the body’s workings, providing clinicians with live images of a patient’s internal organs. To capture these images, trained technicians manipulate ultrasound...